Swiss National Bank lowered its stake in shares of DaVita (NYSE:DVA) by 16.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 470,418 shares of the company’s stock after selling 95,200 shares during the quarter. Swiss National Bank owned about 0.27% of DaVita worth $31,019,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Rhumbline Advisers increased its position in shares of DaVita by 1.3% during the fourth quarter. Rhumbline Advisers now owns 325,210 shares of the company’s stock valued at $23,496,000 after buying an additional 4,055 shares during the period. California State Teachers Retirement System boosted its stake in DaVita by 1.4% during the fourth quarter. California State Teachers Retirement System now owns 274,715 shares of the company’s stock worth $19,848,000 after acquiring an additional 3,711 shares in the last quarter. Segall Bryant & Hamill LLC boosted its stake in DaVita by 10.7% during the fourth quarter. Segall Bryant & Hamill LLC now owns 41,135 shares of the company’s stock worth $2,972,000 after acquiring an additional 3,980 shares in the last quarter. Xact Kapitalforvaltning AB boosted its stake in DaVita by 15.0% during the fourth quarter. Xact Kapitalforvaltning AB now owns 22,819 shares of the company’s stock worth $1,649,000 after acquiring an additional 2,968 shares in the last quarter. Finally, Rock Springs Capital Management LP bought a new stake in DaVita during the fourth quarter worth about $5,787,000. Institutional investors own 89.18% of the company’s stock.
Several equities research analysts recently commented on the stock. SunTrust Banks reissued a “hold” rating and set a $80.00 price objective on shares of DaVita in a research note on Wednesday, February 14th. Robert W. Baird set a $97.00 price objective on shares of DaVita and gave the stock a “buy” rating in a research note on Tuesday, February 13th. Finally, Zacks Investment Research lowered shares of DaVita from a “buy” rating to a “hold” rating in a research note on Tuesday, February 13th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $79.30.
DaVita (NYSE:DVA) last issued its earnings results on Thursday, May 3rd. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.13. The firm had revenue of $2.85 billion for the quarter, compared to the consensus estimate of $2.79 billion. DaVita had a net margin of 2.94% and a return on equity of 13.84%. The business’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.79 earnings per share. research analysts anticipate that DaVita will post 4.1 EPS for the current fiscal year.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita (NYSE:DVA).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.